Open surgical partial nephrectomy for upper tract urothelial carcinoma.

Published

Journal Article

We aimed to determine the ability of partial nephrectomy to prevent end-stage renal disease and tumor recurrence or progression in patients with upper tract urothelial carcinoma. Retrospectively, eight patients undergoing partial nephrectomy for upper tract urothelial carcinoma were identified and their medical records reviewed. All patients had imperative indications for nephron sparing, and diagnosis of upper tract urothelial carcinoma not adequately amenable to endoscopic management. Although three patients suffered acute tubular necrosis, only one required postoperative hemodialysis. During the follow-up period 25% (2/8) developed end-stage renal disease, including the one patient who had received postoperative hemodialysis. Recurrences occurred in five of seven patients with adequate oncological surveillance. Recurrences were successfully treated endoscopically in 80% (4/5) patients, and one patient had metastases. Of the eight patients, four have died. Death occurred 4 months, 1 year, 1.2 years and 3.5 years after partial nephrectomy. Of these patients, one succumbed to metastatic disease; the exact cause of death is unknown in the other three, but there was no documentation of metastatic cancer. The mean duration of follow up in the remaining four patients, all without evidence of metastatic urothelial cancer, is 71 months (range 22-108 months). In summary, partial nephrectomy for upper tract urothelial carcinoma in patients with imperative indications averts end-stage renal disease in most patients, and appears to be associated with acceptable disease-specific survival. Partial nephrectomy is a sparingly used option in patients with upper tract urothelial carcinoma refractory to endoscopic management who have imperative indications for nephron sparing.

Full Text

Duke Authors

Cited Authors

  • Macari, D; Faerber, GJ; Hafez, KS; Hollenbeck, BK; Montie, JE; Wood, DP; Wolf, JS

Published Date

  • April 2014

Published In

Volume / Issue

  • 21 / 4

Start / End Page

  • 409 - 412

PubMed ID

  • 24134309

Pubmed Central ID

  • 24134309

Electronic International Standard Serial Number (EISSN)

  • 1442-2042

Digital Object Identifier (DOI)

  • 10.1111/iju.12301

Language

  • eng

Conference Location

  • Australia